TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05437549

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI
Description: MRI prior to PVI, acutely after PVI, and 3 months after PVI
Study: NCT06038019

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral food challenge
Description: Patients will undergo oral food challenge with increasing amounts of food allergen
Study: NCT05548686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adapted physical activity
Description: 3 sessions of adapted physical activity per week during 12 weeks for each patient
Study: NCT05985681

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample and vaginal swab collection

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample and vaginal swab collection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV16 RG1 VLP Vaccine
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Human Papillomavirus Nonavalent Vaccine
Description: Given via injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant Human Papillomavirus Nonavalent Vaccine
Description: Given via injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Given IM
Study: NCT06642974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education module on learning disabilities
Description: Data will be collected for a period of one -year. samples will be equally distributed among experimental and control group. Socio -demographic data and knowledge and attitude of primary school teachers on learning disability will be assessed by interview method using questionnaire. Control group will receive general information on children with learning disabilities while experimental group will receive education training program. After 15 days again education program will be repeated as a reinforcement. Pre and posttest will be conducted for both the groups at one-month interval. Required data will be collected for one-year period by interview method using questionnaire. Competency assessment will be done by using checklist on identification of learning disabilities Teachers' competency for experimental group then the competency will be verified by education counselor . As a follow up of the research study, after one-month interval no of referral by each teacher will be collected to m

Intervention type: OTHER
Group type: OTHER
Intervention: pamphlet on learning disability
Description: Education pamphlets will be provided to total of 67 samples
Study: NCT05620342

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iC9.GD2.CAR.IL-15 T Infusion
Description: iC9-GD2.CAR.IL-15 T-cells product will be administered via intravenous injection over 5 - 10 minutes.
Study: NCT05881382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutogliptin + Filgrastim
Description: dutogliptin twice daily subcutaneously for 14 days and filgrastim daily subcutaneously for 5 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dutogliptin twice daily subcutaneously for 14 days and placebo filgrastim daily subcutaneously for 5 days.
Study: NCT06500663

Intervention type: OTHER
Intervention: haemodialysis
Description: haemodialysis effect on thyroid function
Study: NCT04000477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytobrush
Description: the brush would be inserted in full until the display of the brush in the endocervical canal disappears. A neck quadrant scan (= quarter turn) will be performed from front to back while simultaneously rotating the brush clockwise, for a total of 3 laps. This would represent 4 sweeps per turn, ie 12 sweeps in total

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kevorkian curette
Description: the colposcopist holds the curette horizontally and scrapes the endocervical canal all the way around. He realizes 1 small firm and linear movement by quarter turn or 4 movements to realize a complete turn. During this act, the curette must remain inside the canal, and during its extraction, care should be taken not to rotate it so as not to spill the collected tissue contained in the basket of the curette. The tissue material thus obtained must be rapidly immersed in formalin
Study: NCT05046756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mHealth App and wearable device
Description: An intervention group (App+IoT device) uses a smart care application for 12 months. This application was tailored for colon cancer patients and created by reflecting the treatment process after surgery. And they also uses a wearable smart band for 12 months.
Study: NCT06546033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: application of different types of diet
Description: application of different types of diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: application of different types of diet
Description: application of different types of diet
Study: NCT05585944

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Genotyping of rs1883832C/T related single-nucleotide polymorphism
Description: Genotyping of rs1883832C/T related single-nucleotide polymorphism by real time pcr

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Genotyping of rs1883832C/T related single-nucleotide polymorphism
Description: Genotyping of rs1883832C/T related single-nucleotide polymorphism by real time pcr
Study: NCT05987176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutathera
Description: Dosage:~In total 14.8 GBq (400 mCi) 177Lu-DOTATATE administered in two equally divided doses. Each dose to be infused over 30 minutes.~Duration of treatment:~Two administrations of 177Lu-DOTATATE (each treatment 7.4 GBQ (200 mCi) at 8±1-week intervals, which can be extended to 16 weeks for resolving acute toxicity.
Study: NCT05188742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: mirabegron 50mg QD
Study: NCT04232657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: 39 subjects with chronic SCI will be studied with a 2:1 ratio of randomization of drug to placebo. Romosozumab (210mg SQ) will be administered once a month for 12 months. Participants will arrive at the JJPVAMC or KIR once a month to receive injections of romosozumab or placebo. A designated unblinded healthcare professional will be responsible for administering these injections.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Because there is a high likelihood that the bone accrued while on romosozumab will be lost once discontinued, denosumab, an anti-resorptive agent, will be administered after treatment with romosozumab, to maintain or, possibly, to continue to increase, bone mineral density. Denosumab will be administered to both groups (treatment and placebo) for an additional 12 months. Participants will be asked to arrive at the JJPVAMC once every 6 months to receive injections of denosumab by a healthcare professional.
Study: NCT05188742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: mirabegron 50mg QD

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TTNS
Description: transcutaneous tibial nerve stimulation
Study: NCT04232657

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Thirteen (13) of the thirty-nine (39) subjects enrolled in this study will be randomly selected to receive placebo (NS SQ) injections for 12 months (baseline - month 11). The placebo injections will be administered by an unblinded healthcare professional (registered nurse / physician). Participants will be blinded to their group assignment (romosozumab treatment or placebo).
Study: NCT05188742

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TTNS
Description: transcutaneous tibial nerve stimulation
Study: NCT04917770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab in combination with Multimodality Radiotherapy
Description: Participants will be treated with sintilimab in combination with multimodality radiotherapy
Study: NCT05237310

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Description: Standard Colonoscopy using a standard Fujifilm colonoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Description: Standard Colonoscopy using a standard Fujifilm colonoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Description: Standard Colonoscopy using a standard Fujifilm colonoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Description: Standard Colonoscopy using a standard Fujifilm colonoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: G-EYE Colonoscopy
Description: G-EYE Colonoscopy performed using SMART Medical G-EYE Colonoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: G-EYE Colonoscopy
Description: G-EYE Colonoscopy performed using SMART Medical G-EYE Colonoscope

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAD-EYE
Description: Colonoscopy performed using with the aid of Fujifilm CAD-EYE artificial intelligence

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAD-EYE
Description: Colonoscopy performed using with the aid of Fujifilm CAD-EYE artificial intelligence

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAD-EYE
Description: Colonoscopy performed using with the aid of Fujifilm CAD-EYE artificial intelligence

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAD-EYE
Description: Colonoscopy performed using with the aid of Fujifilm CAD-EYE artificial intelligence
Study: NCT04826679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab, nab-paclitaxel, cisplatin
Description: Patients receive Camrelizumab IV on day 1, nab-paclitaxel IV on day 1 and cisplatin IV on day 1.~Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
Study: NCT04930796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VER-01
Description: standardised cannabis extract (containing 21 mg THC per gram drug product)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VER-01
Description: standardised cannabis extract (containing 21 mg THC per gram drug product)
Study: NCT05029050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Continous intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Continous intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Natriumchlorid
Description: Continous intravenous infusion NaCl
Study: NCT05531747

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: A maximum of 2 superficial skin biopsies (epidermis/dermis), allowing 10 hair follicles to be obtained, at the edge of the affected area, in healthy territory (excluding the face and folds but not excluding the pubic region), at initiation visit.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: 42mL of blood (6 tubes of 7mL) sampled at initiation visit
Study: NCT05541783

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopy-assisted distal gastrectomy Group
Description: LADG

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Totally laparoscopic distal gastrectomy
Description: TLDG
Study: NCT05106569

Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry
Description: All study participants will undergo pulmonary function testing using conventional spirometry in clinic and portable spirometry in clinic and at home. In-clinic conventional laboratory spirometry is compared with portable spirometry and Slow vital capacity is obtained in upright and supine positions.

Intervention type: DIAGNOSTIC_TEST
Intervention: Spirometry
Description: All study participants will undergo pulmonary function testing using conventional spirometry in clinic and portable spirometry in clinic and at home. In-clinic conventional laboratory spirometry is compared with portable spirometry and Slow vital capacity is obtained in upright and supine positions.
Study: NCT05014061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: Adenosine infusion 70 µg/kg/min for 6 hours
Study: NCT05999162

Intervention type: PROCEDURE
Intervention: Minimally invasive surgery
Description: Minimally invasive surgery includes laparoscopic surgery or robotic surgery for the treatment of colorectal surgery.
Study: NCT05986084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir Injection [Apretude]
Description: Injection
Study: NCT05228847

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Human milk-derived HMF
Description: Fortification with human milk-derived product

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: bovine milk-derived HMF
Description: bovine milk-derived HMF
Study: NCT05808634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BA3182
Description: Conditionally active biologic (CAB)-bispecific T-cell engager antibody construct targeting EpCAM
Study: NCT05402033

Intervention type: BEHAVIORAL
Intervention: Survey / Interview Group
Description: Patients with any cancer type who are informed that they may be eligible for participation in any phase therapeutic cancer clinical trial by their treating physician (typically a clinical oncologist) will be provided information about the Financial Reimbursement Program. Patients who enroll to therapeutic cancer clinical trial will be eligible for the reimbursement program and offered an opportunity to participate in this study.
Study: NCT06160102

Intervention type: OTHER
Group type: OTHER
Intervention: Develop and implement the Framework for safe drug use in people with intellectual and/or developmental disabilities
Description: Collection and analysis of drug lists and information about the users. Open / participatory observations of staff and residents during drug handling. Interviews/focus groups with residents, family, staff in the service, GPs and pharmacy staff. Interdisciplinary drug reviews based on the IMM method drug reviews, further developed by the researchers in the project.~Design thinking. We use a design process with five stages: empathy, define, generate ideas, prototype and test. This involves user participation and experience to design the most optimal solution for the framework.~Evaluate the framework, observations, interviews, questionnaires. Health economic evaluation.
Study: NCT05241249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bethanechol
Description: Study Drug: Bethanechol (generic), supplied as 50mg oral tablets. Subjects will take 2 tablets (100mg) twice daily. Medication should be taken 1 hour before meals in AM and PM. Medication will be purchased commercially and dispensed at the research pharmacy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Non-experimental. Chemotherapy will be administered on a day 1, 8 and 15 schedule with gemcitabine at a dose of 1000 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Non-experimental. Chemotherapy will be administered on a day 1, 8 and 15 schedule with nab-paclitaxel dose at 125 mg/m2
Study: NCT05896007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 160 mg bid po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during the 1st year in 2 years of follow-up

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 ivgtt, D0 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 3.5 g/m\^2 ivgtt, D1 of each 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 150 mg/m\^2 ivgtt, D1-D5 of each 28-day cycle
Study: NCT05932719

Intervention type: OTHER
Intervention: COLLAT-COVID is an observational study based on retrospective data issued from patients medial files.
Description: The following items will be collected~* Diagnostic date~* Diagnostic stage~* Date of surgery~* Date of surgery appointment~* First antineoplastic treatment date~* Last antineoplastic treatment date~* Number of treatment cycles recommanded by MDTM

Intervention type: OTHER
Intervention: COLLAT-COVID is an observational study based on retrospective data issued from patients medial files.
Description: The following items will be collected~* Diagnostic date~* Diagnostic stage~* Date of surgery~* Date of surgery appointment~* First antineoplastic treatment date~* Last antineoplastic treatment date~* Number of treatment cycles recommanded by MDTM
Study: NCT05255003

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: I. Platelet count 25-50,000/µL: 0.5mg/kg subcutaneously twice daily~II. Platelet count \< 25,000/µL: hold anticoagulation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: I. Platelet count 25-50,000/µL: 0.5mg/kg subcutaneously twice daily~II. Platelet count \< 25,000/µL: hold anticoagulation

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin
Description: I. Platelet count 25-50,000/µL: 100 IU/kg subcutaneously daily for the first month of an acute VTE then 75 U/kg~II. Platelet count \< 25,000/µL: hold anticoagulation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dalteparin
Description: I. Platelet count 25-50,000/µL: 100 IU/kg subcutaneously daily for the first month of an acute VTE then 75 U/kg~II. Platelet count \< 25,000/µL: hold anticoagulation

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tinzaparin
Description: I. Platelet count 25-50,000/µL: 87.5 units/kg subcutaneously daily~II. Platelet count \< 25,000/µL: hold anticoagulation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tinzaparin
Description: I. Platelet count 25-50,000/µL: 87.5 units/kg subcutaneously daily~II. Platelet count \< 25,000/µL: hold anticoagulation
Study: NCT04819321

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoolSculpting® System
Description: A treatment is comprised of timed segments of cooling and heating; a vacuum treatment may include an optional massage
Study: NCT05406908

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tozinameran
Description: Pfizer-BioNTech COVID-19 vaccine (Trade name: Comirnaty)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: tozinameran
Description: Pfizer-BioNTech COVID-19 vaccine (Trade name: Comirnaty)
Study: NCT05906732

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LQT-1213
Description: LQT-1213 is a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LQT-1213
Description: LQT-1213 is a serum glucocorticoid regulated kinase 1 (SGK-1) inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dofetilide 250 μg Cap
Description: Dofetilide is a potent, pure inward-rectifier potassium channels (IKr) blocker

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dofetilide 250 μg Cap
Description: Dofetilide is a potent, pure inward-rectifier potassium channels (IKr) blocker
Study: NCT06112964

Intervention type: PROCEDURE
Intervention: MRI/ Functional MRI
Description: Participants will undergo an MRI scan lasting approximately 1 hour to examine the structure and function of the brain. During the scan, they will also be asked to perform computer based tasks. This is called functional MRI.

Intervention type: PROCEDURE
Intervention: MRI/ Functional MRI
Description: Participants will undergo an MRI scan lasting approximately 1 hour to examine the structure and function of the brain. During the scan, they will also be asked to perform computer based tasks. This is called functional MRI.

Intervention type: BEHAVIORAL
Intervention: Self-reported questionnaires
Description: Participants will complete questionnaires covering subjective measures relating to food attitudes and intake, and report-based measures of relevant psychopathology including depression and anxiety. These will be derived from standardised scales already used clinically, including the setting of eating disorders and normative studies of the neuroscience of appetite.

Intervention type: BEHAVIORAL
Intervention: Self-reported questionnaires
Description: Participants will complete questionnaires covering subjective measures relating to food attitudes and intake, and report-based measures of relevant psychopathology including depression and anxiety. These will be derived from standardised scales already used clinically, including the setting of eating disorders and normative studies of the neuroscience of appetite.

Intervention type: BEHAVIORAL
Intervention: Computer based tasks
Description: Participants will complete computer based tasks which are focused specifically on aspects of appetite-related and reward behaviours. Typically, such behaviours are characterised under the following sub-headings:~i) Motivation (the amount of effort, cognitive or physical, that a person is prepared to expend in order to gain access to food), ii) Valuation (the relative rating of foods in comparison to each other and to non-food items), and iii) Hedonic response (the subjective pleasure experienced in consumption) to food intake

Intervention type: BEHAVIORAL
Intervention: Computer based tasks
Description: Participants will complete computer based tasks which are focused specifically on aspects of appetite-related and reward behaviours. Typically, such behaviours are characterised under the following sub-headings:~i) Motivation (the amount of effort, cognitive or physical, that a person is prepared to expend in order to gain access to food), ii) Valuation (the relative rating of foods in comparison to each other and to non-food items), and iii) Hedonic response (the subjective pleasure experienced in consumption) to food intake
Study: NCT05527938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: web-based intervention
Description: 1. Establishing management teams.~2. Establishment of a nursing intervention team.~3. Daily uploading of health intervention records~4. Regularly delivering related health knowledge.~5. Home visiting~6. Psychological guidance. The health teachers in the team should closely understand the psychological trends of the patients during the telephone follow-up and home visits and verbally communicate more with the children to stimulate them to develop good living habits and increase their confidence in healing.
Study: NCT05915039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer Assisted Learning (CAL) Module
Description: The students assigned to Group A will undergo interactive CAL module training by the American Medical Association which outlines how to properly measure blood pressure manually following the American Heart Association guidelines.